These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6088743)

  • 1. [Demonstration of the immunostimulating component(s) in Bordetella pertussis (Phase I, strain Tohama), other than cell wall peptidoglycan, endotoxic lipopolysaccharide and pertussis toxin].
    Kubo T
    Osaka Daigaku Shigaku Zasshi; 1984 Jun; 29(1):138-57. PubMed ID: 6088743
    [No Abstract]   [Full Text] [Related]  

  • 2. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
    Calver GA
    Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of Bordetella endotoxins in bactericidal systems.
    Pusztai Z; Csizér Z; Joó I
    Ann Immunol Hung; 1973; 17():suppl 59-61. PubMed ID: 4376904
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
    Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
    Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outer membrane vesicles as acellular vaccine against pertussis.
    Roberts R; Moreno G; Bottero D; Gaillard ME; Fingermann M; Graieb A; Rumbo M; Hozbor D
    Vaccine; 2008 Aug; 26(36):4639-46. PubMed ID: 18640169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
    Medeiros MA; Armôa GR; Dellagostin OA; McIntosh D
    Can J Microbiol; 2005 Dec; 51(12):1015-20. PubMed ID: 16462859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine.
    Pereira A; Pereira AS; Moreira-Filho CA; Bando SY; Tambourgi DV
    Vaccine; 2005 Jul; 23(34):4353-8. PubMed ID: 16005744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.
    Geurtsen J; Fransen F; Vandebriel RJ; Gremmer ER; de la Fonteyne-Blankestijn LJ; Kuipers B; Tommassen J; van der Ley P
    Vaccine; 2008 Feb; 26(7):899-906. PubMed ID: 18207288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-cell pertussis vaccine protects against Bordetella pertussis exacerbation of allergic asthma.
    Ennis DP; Cassidy JP; Mahon BP
    Immunol Lett; 2005 Feb; 97(1):91-100. PubMed ID: 15626480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role and specificity of bordetella lipopolysaccharide in immune reactions.
    Pusztai Z; Csizér Z; Joó I
    Z Immunitatsforsch Allerg Klin Immunol; 1971; 141(2):129-40. PubMed ID: 4323220
    [No Abstract]   [Full Text] [Related]  

  • 11. [An observation on immunization reaction and serological effect of adsorbed purified pertussis vaccine].
    Tian X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):155-9. PubMed ID: 8221838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America.
    Bottero D; Gaillard ME; Basile LA; Fritz M; Hozbor DF
    J Appl Microbiol; 2012 Jun; 112(6):1266-76. PubMed ID: 22471652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled Bordetella pertussis vaccine decreases airway responsiveness in guinea pigs.
    Vargas MH; Bazán-Perkins B; Segura P; Campos MG; Selman M; Montaño LM
    Life Sci; 1995; 57(19):PL293-9. PubMed ID: 7475913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines.
    Geurtsen J; Vandebriel RJ; Gremmer ER; Kuipers B; Tommassen J; van der Ley P
    Microbes Infect; 2007 Jul; 9(9):1096-103. PubMed ID: 17644385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism between two immunogens extracted from Brucella (cell wall peptidoglycan and lipopolysaccharide fractions) and inactivity of the brucellin allergen in immunization of the mouse.
    Bosseray N; Plommet M
    Ann Microbiol (Paris); 1980; 131A(2):157-69. PubMed ID: 7387055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis.
    Cainelli Gebara VC; Risoléo L; Lopes AP; Ferreira VR; Quintilio W; Lépine F; Silva WD; Raw I
    Vaccine; 2007 Jan; 25(4):621-9. PubMed ID: 17011680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of pertussis vaccines.
    Brennan MJ; Burns DL; Meade BD; Shahin RD; Manclark CR
    Biotechnology; 1992; 20():23-52. PubMed ID: 1600382
    [No Abstract]   [Full Text] [Related]  

  • 20. Bordetella pertussis strain variation and evolution postvaccination.
    Kallonen T; He Q
    Expert Rev Vaccines; 2009 Jul; 8(7):863-75. PubMed ID: 19538113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.